Answers are grounded in this paper and cite their sources.
proliferative state and postulated agents targeting cycling cells would enhance engraftment. When we administered the antimetabolite 5-fluorouracil with anti-CD117-sap, anti-thymocyte globulin, and an immunoglobulin-degrading enzyme, we achieved >90% peripheral blood chimerism of unmodified cultured donor cells. Additional immunosuppression combined with an increase in transplanted cells further permitted ∼70% engraftment of HSPCs transduced with an LV encoding a high-expression, immunogenic factor VIII (FVIII) transgene. Copy numbers of ∼1.0 and normal FVIII plasma activity levels (>50%) by 6 months post-HSCT were achieved. Collectively, we show ADC and antimetabolite administration can augment LV-engineered HSPC engraftment by targeting cycling cells.
No takes yet. Share an insight, caveat, or question.
Okáľová et al. (2026) studied this question.